Status:

TERMINATED

Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)

Lead Sponsor:

MedImmune LLC

Conditions:

RSV Infection

Eligibility:

All Genders

18-45 years

Phase:

PHASE1

Brief Summary

The primary objective is to evaluate the suitability of the challenge model in measuring the efficacy of MEDI-557 compared to placebo in healthy adult participants for the reduction in the incidence o...

Detailed Description

This is designed to be a double-blind, placebo-controlled, randomized study. Approximately 30 participants will be randomized, dosed and followed. Participants will be randomly assigned to receive a s...

Eligibility Criteria

Inclusion

  • Healthy as determined by medical history and physical examination.
  • Age 19 through 38 years at the time of screening.
  • Written informed consent and any locally required authorization obtained from the subject prior to performing any protocol-related procedures, including screening evaluations.
  • Weight less than or equal to (\<=) 10 kilogram (kg) with body mass index (BMI) less than (\<) 32 kilogram per meter square (kg/m\^2).
  • Normotensive (systolic blood pressure \[BP\] \<150 millimeters of mercury (mmHg) and diastolic BP \< 90 mmHg).
  • Females of childbearing age using contraception.
  • Males who are sexually active with a female partner of childbearing potential, using contraception.
  • Sero-suitable (that is, low serum RSV neutralizing antibody titre) for RSV infection.

Exclusion

  • Current medical conditions as follows:
  • Clinical evidence of chronic pulmonary disease or any use of a bronchodilator or other asthma medication.
  • Current smoker unwilling/unable to desist for the quarantine phase of the study.
  • History or clinical evidence of recurrent lower respiratory tract infection.
  • Evidence of infection with hepatitis A, B, or C virus or human immunodeficiency virus (HIV) by serology.
  • Medical history as follows:
  • History of immunodeficiency.
  • History of chronic sinusitis.
  • History of frequent epistaxis.
  • History of or current diagnosis of diabetes.
  • Prior/concomitant therapy including
  • Receipt of any systemic chemotherapeutic agent at any time;
  • Receipt of systemic glucocorticoids within 1 month, or any other immunosuppressive drug within 6 months prior to challenge.
  • Receipt of any investigational drug within 6 months prior to dose or concurrent enrolment in another clinical study.
  • Prior participation in a clinical trial of any experimental RSV viral challenge delivered directly to the respiratory tract at any time, or any other respiratory virus challenge within 1 year prior to dose.
  • Nursing mother.
  • Alcohol or drug addiction/abuse within the past 2 years.
  • A positive urine Class A drug or alcohol screen unless there is a medical reason.
  • History of seasonal hay fever or seasonal allergies.
  • Employees of the clinical study site or sponsor, any other individuals involved with the conduct of the study, or immediate family members of such individuals.
  • Health care workers anticipated to have patient contact within 2 weeks after viral challenge.
  • Participants who, for an additional 2 weeks after discharge from the isolation facility, are likely to have contact with a household member or close contact with someone who is: (a) less than 3 years of age; (b) any person with any known immunodeficiency; (c) any person receiving immunosuppressant medications; (d) any person undergoing or soon to undergo cancer chemotherapy within 28 days of challenge; (e) any person who has diagnosed emphysema or COPD, is elderly residing in a nursing home, or with severe lung disease or medical condition; or (f) any person who has received a transplant (bone marrow or solid organ).
  • As a result of the medical interview, physical examination, or screening investigations, the investigator(s) considers the participant unfit for the study.

Key Trial Info

Start Date :

October 20 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 13 2012

Estimated Enrollment :

7 Patients enrolled

Trial Details

Trial ID

NCT01475305

Start Date

October 20 2011

End Date

December 13 2012

Last Update

July 21 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

London, United Kingdom, E1 2AX